JP2017518748A5 - - Google Patents

Download PDF

Info

Publication number
JP2017518748A5
JP2017518748A5 JP2016568907A JP2016568907A JP2017518748A5 JP 2017518748 A5 JP2017518748 A5 JP 2017518748A5 JP 2016568907 A JP2016568907 A JP 2016568907A JP 2016568907 A JP2016568907 A JP 2016568907A JP 2017518748 A5 JP2017518748 A5 JP 2017518748A5
Authority
JP
Japan
Prior art keywords
polypeptide
glu
gly
arg
lipocalin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016568907A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017518748A (ja
JP6753784B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/061034 external-priority patent/WO2015177175A2/en
Publication of JP2017518748A publication Critical patent/JP2017518748A/ja
Publication of JP2017518748A5 publication Critical patent/JP2017518748A5/ja
Application granted granted Critical
Publication of JP6753784B2 publication Critical patent/JP6753784B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016568907A 2014-05-22 2015-05-20 特異的結合ポリペプチドおよびその使用 Expired - Fee Related JP6753784B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14169488 2014-05-22
EP14169488.5 2014-05-22
PCT/EP2015/061034 WO2015177175A2 (en) 2014-05-22 2015-05-20 Novel specific-binding polypeptides and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020139064A Division JP7084965B2 (ja) 2014-05-22 2020-08-20 特異的結合ポリペプチドおよびその使用

Publications (3)

Publication Number Publication Date
JP2017518748A JP2017518748A (ja) 2017-07-13
JP2017518748A5 true JP2017518748A5 (enExample) 2018-06-28
JP6753784B2 JP6753784B2 (ja) 2020-09-09

Family

ID=50771150

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016568907A Expired - Fee Related JP6753784B2 (ja) 2014-05-22 2015-05-20 特異的結合ポリペプチドおよびその使用
JP2020139064A Expired - Fee Related JP7084965B2 (ja) 2014-05-22 2020-08-20 特異的結合ポリペプチドおよびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020139064A Expired - Fee Related JP7084965B2 (ja) 2014-05-22 2020-08-20 特異的結合ポリペプチドおよびその使用

Country Status (14)

Country Link
US (2) US10774119B2 (enExample)
EP (2) EP3145945B1 (enExample)
JP (2) JP6753784B2 (enExample)
KR (1) KR20170004011A (enExample)
CN (2) CN113621050A (enExample)
AU (2) AU2015261968B2 (enExample)
BR (1) BR112016027024A2 (enExample)
CA (2) CA2949405C (enExample)
DK (1) DK3145945T3 (enExample)
ES (1) ES2823563T3 (enExample)
MX (2) MX384363B (enExample)
RU (1) RU2723034C2 (enExample)
SG (2) SG10201912019WA (enExample)
WO (1) WO2015177175A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10526384B2 (en) 2012-11-19 2020-01-07 Pieris Pharmaceuticals Gmbh Interleukin-17A-specific and interleukin-23-specific binding polypeptides and uses thereof
CA2949405C (en) 2014-05-22 2023-08-01 Pieris Pharmaceuticals Gmbh Novel specific-binding polypeptides and uses thereof
CN108699162A (zh) * 2015-11-30 2018-10-23 皮里斯澳大利亚有限公司 新型抗血管生成融合多肽
NZ756763A (en) 2017-02-17 2023-04-28 Denali Therapeutics Inc Engineered transferrin receptor binding polypeptides
US11077199B2 (en) 2017-08-09 2021-08-03 Massachusetts Institute Of Technology Albumin binding peptide conjugates and methods thereof
HUE063021T2 (hu) * 2017-08-10 2023-12-28 Denali Therapeutics Inc Mesterségesen elõállított transzferrin receptor-kötõ polipeptidek
ES3064335T3 (en) 2018-03-05 2026-04-24 Janssen Biotech Inc Methods of treating crohn's disease with anti-il23 specific antibody
CN112513099A (zh) * 2018-05-31 2021-03-16 香港理工大学 用于癌症、肥胖症、代谢紊乱和相关并发症及合并症的精氨酸耗竭剂的组合物和应用
EP3599245A1 (en) * 2018-07-27 2020-01-29 Dompé farmaceutici S.p.A. Il-17a binding polypeptides and medical uses thereof
CN109096373B (zh) * 2018-09-27 2022-06-21 江苏亨瑞生物医药科技有限公司 合成寡肽及其用途
CN109180789B (zh) * 2018-09-27 2022-08-19 上海揽微赛尔生物科技有限公司 一种寡肽及制药应用
CN109206485B (zh) * 2018-09-27 2022-04-08 山东聚胜生物科技有限公司 一种防治肺癌转移的寡肽
CN109096374B (zh) * 2018-09-27 2022-11-18 深圳乐土沃森精准医疗有限公司 一种抑制肺癌转移的合成寡肽
US20220168387A1 (en) * 2019-03-29 2022-06-02 Pieris Pharmaceuticals Gmbh Inhaled administration of lipocalin muteins
JP2023524125A (ja) * 2020-05-05 2023-06-08 ヤンセン バイオテツク,インコーポレーテツド 抗il23特異的抗体によるクローン病の治療方法
CN114805546B (zh) * 2022-06-08 2024-05-28 宁波市健康口腔医学研究院 一种检测口腔癌的t细胞表位多肽及其应用
WO2025170982A2 (en) 2024-02-06 2025-08-14 Paragon Therapeutics, Inc. Il-23 antibody compositions and methods of use
WO2025226984A1 (en) * 2024-04-24 2025-10-30 Mopac Biologics, Inc. Human il-17 binding polypeptides

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2032831T5 (es) 1986-08-19 2001-02-16 Genentech Inc Dispositivo y dispersion para suministro intrapulmonar de factores de crecimiento polipeptidos y citoquinas.
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンaの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
NZ285664A (en) 1994-05-18 1998-07-28 Inhale Therapeutic Syst Dry powder interferon composition adapted for pulmonary delivery
DE4417598A1 (de) 1994-05-19 1995-12-14 Max Planck Gesellschaft Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen
WO1996023879A1 (en) 1995-01-30 1996-08-08 Terrapin Technologies, Inc. Glubodies - multiplicities of proteins capable of binding a variety of small molecules
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
DE19641876B4 (de) 1996-10-10 2011-09-29 Iba Gmbh Streptavidinmuteine
WO1998016873A1 (en) 1996-10-14 1998-04-23 Firm Forsat Ltd. Method for preparing dispersions of chromogenic components
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
CN1170543C (zh) 1998-06-08 2004-10-13 弗·哈夫曼-拉罗切有限公司 PEG-IFN-α和三唑核苷在治疗慢性丙型肝炎中的用途
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
DE19926068C1 (de) 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
EP1377306A1 (en) 2001-03-09 2004-01-07 Dyax Corp. Serum albumin binding moieties
EP1430136A1 (en) 2001-09-27 2004-06-23 Pieris ProteoLab AG Muteins of apolipoprotein d
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
US7691970B2 (en) 2003-08-25 2010-04-06 Pieris Ag Muteins of a bilin-binding protein with affinity for a given target
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
JP2007284351A (ja) 2004-07-27 2007-11-01 Osaka Bioscience Institute アミロイド蛋白質の凝集を抑制する物質とその作用
EP2899277A1 (en) 2004-11-26 2015-07-29 Pieris AG Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
WO2007038619A2 (en) 2005-09-27 2007-04-05 Amunix, Inc. Proteinaceous pharmaceuticals and uses thereof
WO2007147019A2 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
TW200815469A (en) * 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
CN101516907B (zh) * 2006-08-01 2015-08-26 皮里斯股份公司 泪液脂质运载蛋白的突变蛋白及其获得方法
SG173332A1 (en) 2006-08-01 2011-08-29 Pieris Ag Muteins of tear lipocalin and methods for obtaining the same
DK2426144T3 (en) 2007-02-23 2019-01-07 Merck Sharp & Dohme Manipulated Anti-IL-23P19 Antibodies
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
EP2235053A1 (en) 2007-10-19 2010-10-06 Abbott Laboratories Glycosylated mammalian ngal and use thereof
CN106986926A (zh) * 2008-01-30 2017-07-28 皮里斯股份公司 具有对人c‑met受体酪氨酸激酶的亲和性的泪脂质运载蛋白的突变蛋白及其获得方法
EP3381933B1 (en) 2008-06-24 2020-06-03 Technische Universität München Muteins of hngal and related proteins with affinity for a given target
EP2330897A4 (en) * 2008-09-18 2013-11-27 Univ Columbia NGAL-BINDING SIDEROPHORES AND THEIR USE FOR THE TREATMENT OF IRON DEFICIENCY AND IRON SURPLUS
EP2510357B1 (en) 2009-12-07 2016-03-30 Pieris AG Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target
AU2011263786B2 (en) 2010-06-08 2014-11-13 Astrazeneca Ab Tear lipocalin muteins binding IL-4 R alpha
NZ604805A (en) 2010-07-09 2014-09-26 Affibody Ab Polypeptides
CN103154023B (zh) 2010-08-16 2017-04-05 皮里斯制药有限公司 铁调素的结合蛋白
US9260492B2 (en) 2010-11-15 2016-02-16 Pieris Ag Muteins of human lipocalin 2 with affinity for glypican-3 (GPC-3)
GB201100282D0 (en) * 2011-01-07 2011-02-23 Ucb Pharma Sa Biological methods
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
WO2013087660A1 (en) * 2011-12-13 2013-06-20 Pieris Ag Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors
US10526384B2 (en) 2012-11-19 2020-01-07 Pieris Pharmaceuticals Gmbh Interleukin-17A-specific and interleukin-23-specific binding polypeptides and uses thereof
US10927154B2 (en) * 2014-01-13 2021-02-23 Pieris Pharmaceuticals Gmbh Multi-specific polypeptide useful for localized tumor immunomodulation
CA2949405C (en) 2014-05-22 2023-08-01 Pieris Pharmaceuticals Gmbh Novel specific-binding polypeptides and uses thereof
RU2720688C2 (ru) 2015-01-28 2020-05-12 ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ Новые белки, специфические в отношении ангиогенеза
AU2016221816B2 (en) 2015-02-18 2020-07-02 Pieris Pharmaceuticals Gmbh Novel proteins specific for pyoverdine and pyochelin
AU2016258952C1 (en) 2015-05-04 2020-12-24 Pieris Pharmaceuticals Gmbh Proteins specific for CD137
US10273275B2 (en) 2015-05-18 2019-04-30 Pieris Pharmaceuticals Gmbh Muteins of human lipocalin 2 with affinity for glypican-3 (GPC3) and methods of use thereof
TW201725212A (zh) 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白

Similar Documents

Publication Publication Date Title
RU2016149596A (ru) Новые полипептиды со специфическим связыванием и пути их применения
JP2018532372A5 (enExample)
JP2014502149A5 (enExample)
JP6475630B2 (ja) ストレプトアビジン突然変異タンパク質およびそれらを使用する方法
Alfthan et al. Properties of a single-chain antibody containing different linker peptides
Dübel et al. Bifunctional and multimeric complexes of streptavidin fused to single chain antibodies (scFv)
JP2019506140A5 (enExample)
JP3474574B2 (ja) 結合特異性を有する組換ジスルフィド安定化ポリペプチドフラグメント
JP2017527272A5 (enExample)
JP2018519802A5 (enExample)
US8426557B2 (en) IGF-1R binding polypeptides and their use
Mann et al. Characterization of proteolytic fragments of the laminin‐nidogen complex and their activity in ligand‐binding assays
KR102151289B1 (ko) Abd 결합 폴리펩티드
JP2018515084A5 (enExample)
JP2022500076A5 (enExample)
JP2020505948A5 (enExample)
JP2003518075A5 (enExample)
JP2018519803A5 (enExample)
RU2019122482A (ru) Мутеины липокалина с аффинностью связывания в отношении lag-3
KR20180002855A (ko) 항암 융합 폴리펩타이드
RU2017128105A (ru) Новые белки, специфические в отношении ангиогенеза
CN105968204A (zh) 一种抗前列腺特异性膜抗原的单域重链抗体
CN105968201A (zh) 针对前列腺特异性膜抗原的单域重链抗体
AU2019380620B2 (en) Novel triple-helical polypeptides lacking binding affinity for the Fc domain of immunoglobulin and uses thereof
CA2649589A1 (en) Novel polypeptides and use thereof